IBRX's logo.
Ticker Symbol: IBRX

ImmunityBio Inc

$7.07 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001326110

Company Profile

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 3530 John Hopkins Ct
CEO: Patrick Soon-Shiong
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.43
Change: -$0.09 ( -6.21%)
Days Range: $1.43 - $1.54
Beta: 2.78
52wk. High: $7.10
52wk. Low: $1.21
Ytd. Change -76.03%
50 Day Moving Average: $1.51
200 Day Moving Average: $2.31
Shares Outstanding: 667589845

Valuation

Market Cap: 95.8B
PE Ratio: -
EPS (TTM): -1.13

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A